PatrickG.PilieMD

PubMed

• A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
  Ana M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, Jiun-Sheng Chen, Miao Zhang, Jingjing Liu, Shuai Guo, Patrick G Pilie, Yao Yu, Xingzhi Song, Haswanth Vundavilli,...> ;Clinical Cancer Research. 2024 Apr 29
• Ataxia-Telangiectasia Mutated (ATM) loss of function displays variant and tissue-specific differences across tumor types.
  Pilie, P., Giuliani, V., Wang, W., McGrail, D., Bristow, C., Ngoi, N., Kyewalabye, K., Wani, K., Le, H., Campbell, E., Sánchez, N., Yang, D., Gheeya, J., Goswamy, R., ...> ;Clinical Cancer Research. 2024 Feb 28
• Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.
  Slack-Tidwell, R., Zhu, K., San Lucas, F., Siddiqui, B., Soundararajan, R., Viscuse, P., Zhang, M., Rohra, P., Konnick, E., Pilie, P., Logothetis, C., Corn, P., Subudh...> ;Cancers. 2023 Dec 14
• 7 citations
  Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.
  Anqi Wang, Jiayi Shen, Alex A Rodriguez, Edward J Saunders, Fei Chen, Rohini Janivara, Burcu F Darst, Xin Sheng, Yili Xu, Alisha J Chou, Sara Benlloch, Tokhir Dadaev, ...> ;Nature Genetics. 2023 Dec 1
• Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
  Omar Alhalabi, Nathaniel Wilson, Lianchun Xiao, Yiyun Lin, Jaanki Khandelwal, Mohammad Jad Moussa, Pavlos Msaouel, Neema Navai, Jianjun Gao, Ashish M Kamat, Patrick Pi...> ;European Urology Oncology. 2023 Dec 1
• 1 citations
  SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
  Chuandong Geng, Man-Chao Zhang, Ganiraju C Manyam, Jody V Vykoukal, Johannes F Fahrmann, Shan Peng, Cheng Wu, Sanghee Park, Shakuntala Kondraganti, Daoqi Wang, Brian D...> ;Clinical Cancer Research. 2023 Nov 1
• 1 citations
  SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
  Xian-De Liu, Yan-Ting Zhang, Daniel J McGrail, Xuesong Zhang, Truong Lam, Anh Hoang, Elshad Hasanov, Ganiraju Manyam, Christine B Peterson, Haifeng Zhu, Shwetha V Kuma...> ;Clinical Cancer Research. 2023 Oct 2
• 26 citations
  Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.
  Chad Tang, Alexander D Sherry, Cara Haymaker, Tharakeswara Bathala, Suyu Liu, Bryan Fellman, Lorenzo Cohen, Ana Aparicio, Amado J Zurita, Alexandre Reuben, Enrica Marm...> ;JAMA Oncology. 2023 Jun 1
• 6 citations
  Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components.
  Rama Soundararajan, Paul Viscuse, Patrick Pilie, Jingjing Liu, Souzana Logotheti, Caddie Laberiano Fernández, Daniele Lorenzini, Anh Hoang, Wei Lu, Luisa Maren Solis S...> ;Cancers. 2022 Jun 30
• 19 citations
  Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.
  Daniel J. McGrail, Patrick G. Pilie, Hui Dai, Truong Nguyen Anh Lam, Yulong Liang, Leonie Voorwerk, Marleen Kok, Xiang Zhang, Jeffrey M. Rosen, Amy B. Heimberger, Chri...> ;Science Translational Medicine. 2021 Oct 27
• 45 citations
  Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016.
  Ahmed O. Elmehrath, Ahmed M. Afifi, Muneer J. Al-Husseini, Anas M. Saad, Nathaniel R. Wilson, Kyrillus S. Shohdy, Patrick G. Pilie, Mohamad Bassam Sonbol, Omar Alhalabi> ;JAMA Network Open. 2021 Aug 2
• 41 citations
  ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
  Zhe Tang, Patrick G. Pilie, Chuandong Geng, Ganiraju C. Manyam, Guang Yang, Sanghee Park, Daoqi Wang, Shan Peng, Cheng Wu, Guang Peng, Timothy A. Yap, Paul G. Corn, Br...> ;Clinical Cancer Research. 2021 Sep 1
• 19 citations
  PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer.
  Cheng Wu, Shan Peng, Patrick G. Pilie, Chuandong Geng, Sanghee Park, Ganiraju C. Manyam, Yungang Lu, Guang Yang, Zhe Tang, Shakuntala Kondraganti, Daoqi Wang, Courtney...> ;Molecular Cancer Therapeutics. 2021 Jun 22
• 2 citations
  Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembro...
  Daniel J. McGrail, Patrick G. Pilie, Naim U. Rashid, Leonie Voorwerk, Maarten Slagter, Marleen Kok, Eric Jonasch, Mustafa Khasraw, Amy B. Heimberger, NT Ueno, Renata F...> ;Annals of Oncology. 2021 Jun 21
• 505 citations
  High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
  Daniel J. McGrail, Patrick G. Pilie, Naim U. Rashid, Leonie Voorwerk, Maarten Slagter, Marleen Kok, Eric Jonasch, Mustafa Khasraw, Amy B. Heimberger, Bora Lim, NT Ueno...> ;Annals of Oncology. 2021 Mar 15
• 4 citations
  Patient selection biomarker strategies for PARP inhibitor therapy
  Patrick G. Pilie, Angela George, Timothy A. Yap> ;Annals of Oncology. 2020 Dec 1
• 101 citations
  PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
  Xian De Liu, Wen Kong, Christine B. Peterson, Daniel J. McGrail, Anh Hoang, Xuesong Zhang, Truong Nguyen Anh Lam, Patrick G. Pilie, Haifeng Zhu, Kathryn E. Beckermann,...> ;Nature Communications. 2020 May 1
• 210 citations
  PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
  Patrick G. Pilie, Lauren Averett Byers, Mark J. O'Connor, Timothy A. Yap> ;Clinical Cancer Research. 2019 Jul 1
• 6 citations
  Durable complete response in renal cell carcinoma clinical trials.
  Patrick G. Pilie, Eric Jonasch> ;Lancet. 2019 May 9
• SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinoma.
  Patrick G. Pilie, Eric Jonasch> ;Oncotarget. 2019 Feb 22
• 625 citations
  State-of-the-art strategies for targeting the DNA damage response in cancer
  Patrick G. Pilie, Chad Tang, Gordon B. Mills, Timothy A. Yap> ;Nature Reviews. Clinical Oncology. 2019 Feb 1
• 137 citations
  Development of PARP and Immune-Checkpoint Inhibitor Combinations
  Ross A. Stewart, Patrick G. Pilie, Timothy A. Yap> ;Cancer Research. 2018 Dec 15
• 45 citations
  Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.
  Eric Jonasch, Ian E. McCutcheon, Dan S. Gombos, Kamran Ahrar, Nancy D. Perrier, Diane Liu, Christine C Robichaux, Mercedes F Villarreal, Justin A. Weldon, Ashley H. Wo...> ;The Lancet. Oncology. 2018 Oct 1
• Broadening the View of Germline Mutations in Kidney Cancer.
  Patrick G. Pilie, Kathleen A. Cooney> ;JAMA Oncology. 2018 Sep 1
• 13 citations
  Pilot study of dovitinib in patients with von Hippel-Lindau disease.
  Patrick G. Pilie, Elshad Hasanov, Surena F. Matin, Ashley H. Woodson, Valerie D. Marcott, Shelly Bird, Rebecca Slack, Gregory N. Fuller, Ian E. McCutcheon, Eric Jonasch> ;Oncotarget. 2018 May 4
• Join now to see all